SecBot SecBot

UA

Under Armour, Inc.
NYSE· Apparel & Other Finishd Prods of Fabrics & Similar Matl· Inc. MD· CIK 0001336917 Consumer & Retail
$4.67 −0.04 (−0.85%)
Nov 16 4:00 PM ET · prev $4.71
Market cap
$2.0B
Mid cap
1 year
+15.0%
from $4.06 · Nov 17
30 days
+0.9%
from $4.63
52-week range
$3.96–7.88
−41% from high · low Nov 20
Avg volume 20D
2.58M
shares / day
Short interest
24.53M
≈5.7% of shares · −1.1%
Days to cover
12.4
at average volume
Insider net
+$6.0M
2 buyers · 0 sellers · since Apr 1
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read BULLISH 1 report · latest
Balance 0 bearish · 1 bullish oldest → newest, height = score
Avg score

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $6.0M at an average $4.99. No open-market sales. Price is 6% below their cost.

  • InstitutionsMIXED

    Q3 2026: 14 added (0 new), 13 trimmed or exited.

  • Short sellersSTEADY

    Short interest −1.1% to 24.53M shares. 12.4 days to cover, ≈5.7% of shares.

  • TrendRANGE

    2% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
AMERICAN CENTURY COMPANIES INCDOUBLED1,531,811$6.7M
UBS Group AGADD904,169$3.9M
PUBLIC SECTOR PENSION INVESTMENT BOARDADD742,122$3.5M
Quantinno Capital Management LPTRIM468,153$2.0M
JPMORGAN CHASE & CODOUBLED452,955$1.9M
Squarepoint Ops LLCADD182,583$794.2K
BARCLAYS PLCDOUBLED144,008$626.4K
IMC-Chicago, LLCADD74,766$325.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jun 2024
Recent actions
DateFirmActionRating
Jun 24, 2024Stifel
MAINTAIN
MAINTAINBuy
Oct 26, 2022Citigroup
MAINTAIN
MAINTAINNeutral
Feb 2, 2022Morgan Stanley
UPGRADE
UPGRADEOverweight
Feb 12, 2020Credit Suisse
MAINTAIN
MAINTAINNeutral
May 17, 2019JP Morgan
UPGRADE
UPGRADEOverweight
Feb 14, 2018JP Morgan
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$6.0M
bought · 2 insiders
$0
sold · 0 insiders
−6.4%
vs their $4.99 cost
DateInsiderTypeValue
Oct 1, 2026
El-Erian Mohamed
Director
Oct 1, 2026
AWARD14,624.72 sh
Oct 1, 2026
COLTHARP DOUGLAS E
Director
Oct 1, 2026
AWARD7,864.24 sh
Oct 1, 2026
Everson Carolyn
Director
Oct 1, 2026
AWARD1,103.75 sh
Oct 1, 2026
Fitzpatrick Dawn N.
Director
Oct 1, 2026
AWARD6,070.64 sh
Oct 1, 2026
Gibbs David W
Director
Oct 1, 2026
AWARD6,346.58 sh
Oct 1, 2026
Sweeney Robert John
Director
Oct 1, 2026
AWARD6,070.64 sh
Oct 1, 2026
Whitesell Patrick
Director
Oct 1, 2026
AWARD5,518.76 sh
Aug 28, 2026
Pestridge Simon James
Chief Marketing Officer
Aug 28, 2026
TAX W/H3,679 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
24,527,925
shares short
-1.1%
vs prior settlement
12.4
days to cover
≈5.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Oct 1, 2026 Insider
El-Erian Mohamed was granted 14,624.72 shares
Director
Oct 1, 2026 Insider
COLTHARP DOUGLAS E was granted 7,864.24 shares
Director
Oct 1, 2026 Insider
Everson Carolyn was granted 1,103.75 shares
Director
Sep 30, 2026 Inst.
AMERICAN CENTURY COMPANIES INC · DOUBLED
1,531,811 shares ($6.7M)
Sep 30, 2026 Inst.
UBS Group AG · ADD
904,169 shares ($3.9M)
Aug 12, 2026 SEC
Under Armour CFO Reza Taleghani made a $100K open-market purchase of 18,656 shares at $5.37 on August 11, 2026. This…
INSIDER-BUY · Impact 5/10
May 12, 2026 SEC
Under Armour reported Q4 FY2026 revenue of $1.17B, roughly in line with consensus, but posted a GAAP diluted loss per…
8-K · Impact 7/10
Mar 17, 2026 Drug approval
EMA: Human medicines European public assessment report (EPAR): Daybu, trofinetide, Status: Opinion under re-examination
Human medicines European public assessment report (EPAR): Daybu, trofinetide, Status: Opinion under
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Mar 17, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Daybu, trofinetide, Status: Opinion under re-examination
Human medicines European public assessment report (EPAR): Daybu, trofinetide, Status: Opinion under re-examination
Mar 10, 2026
Drug approval
EMA: Human medicines European public assessment report (EPAR): Iloperidone Vanda Pharmaceuticals, iloperidone, Status: Opinion under re-examination
Human medicines European public assessment report (EPAR): Iloperidone Vanda Pharmaceuticals, iloperidone, Status: Opinion under re-examination
Feb 27, 2026
Short interest
FTD: UA, 280,143 shares ($2.1M) failed to deliver
Settlement: 20260227, Price: $7.38, FTD Value: $2,067,455.34, UNDER ARMOUR INC CL C
Feb 2, 2026
Short interest
FTD: UA, 118,483 shares ($0.7M) failed to deliver
Settlement: 20260202, Price: $6.07, FTD Value: $719,191.81, UNDER ARMOUR INC CL C

SecBot reports

2 filings · 1 bullish · 1 bearish
All UA filing & press-release reports (2)